Latest Filings

Issuer Activity

Insider Overview :: Cangene Corporation (T:CNJ) [?]
Business Focus: Biopharmaceuticals
Recent Price for CNJ
CAD 2.96 0.00 (0.00%)
TSX Delayed 15 minutes
May 21 1528 EDT
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
N/A 3.28 0.0 N/A 197.57
1-Day Low 52-Week Low Yield Avg. Volume  
N/A 1.40 0.0% 6,717  
Log in or sign up for a free account to add this stock to your watch list.
Holdings trends & enhanced charts available in PDF report. Click here for details »
Latest 10 SEDI filings (by transaction date) for CNJ within the last 6 months [?]
Amended Filing
As of 11:59pm ET May 21st, 2013
Filing
Date 		Transaction
Date 		Insider Name Ownership
Type 		Securities Nature of transaction # or value acquired or disposed of Price
May 1/13 May 1/13 Lillibridge, Robin Scott Direct Ownership Rights Deferred Share Units (cash settled) 56 - Grant of rights 6,780 $2.95
USD
May 1/13 May 1/13 Johnson, Philip Rudolph Direct Ownership Rights Deferred Share Units (cash settled) 56 - Grant of rights 2,373 $2.95
USD
May 1/13 May 1/13 Burlington, Donald Bruce Direct Ownership Rights Deferred Share Units (cash settled) 56 - Grant of rights 3,390 $2.95
USD
May 1/13 May 1/13 Desai, Jeremy Bharat Direct Ownership Rights Deferred Share Units (cash settled) 56 - Grant of rights 6,780 $2.95
May 1/13 May 1/13 Lavery, John Robert Direct Ownership Rights Deferred Share Units (cash settled) 56 - Grant of rights 1,695 $2.95
May 1/13 May 1/13 Kay, Jack Moses Direct Ownership Rights Deferred Share Units (cash settled) 56 - Grant of rights 6,780 $2.95
Mar 25/13 Mar 21/13 Sherman, Bernard Charles Control or Direction Common Shares 47 - Disposition by gift -2,003,000  
Feb 1/13 Feb 1/13 Lavery, John Robert Direct Ownership Rights Deferred Share Units (cash settled) 56 - Grant of rights 2,858 $1.75
Feb 1/13 Feb 1/13 Kay, Jack Moses Direct Ownership Rights Deferred Share Units (cash settled) 56 - Grant of rights 11,429 $1.75
Feb 1/13 Feb 1/13 Desai, Jeremy Bharat Direct Ownership Rights Deferred Share Units (cash settled) 56 - Grant of rights 11,429 $1.75
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Latest 10 SEDI filings (by filing date) for CNJ within the last 6 months [?]
Amended Filing
As of 11:59pm ET May 21st, 2013
Filing
Date 		Transaction
Date 		Insider Name Ownership
Type 		Securities Nature of transaction # or value acquired or disposed of Price
May 1/13 May 1/13 Lillibridge, Robin Scott Direct Ownership Rights Deferred Share Units (cash settled) 56 - Grant of rights 6,780 $2.95
USD
May 1/13 May 1/13 Johnson, Philip Rudolph Direct Ownership Rights Deferred Share Units (cash settled) 56 - Grant of rights 2,373 $2.95
USD
May 1/13 May 1/13 Burlington, Donald Bruce Direct Ownership Rights Deferred Share Units (cash settled) 56 - Grant of rights 3,390 $2.95
USD
May 1/13 May 1/13 Desai, Jeremy Bharat Direct Ownership Rights Deferred Share Units (cash settled) 56 - Grant of rights 6,780 $2.95
May 1/13 May 1/13 Lavery, John Robert Direct Ownership Rights Deferred Share Units (cash settled) 56 - Grant of rights 1,695 $2.95
May 1/13 May 1/13 Kay, Jack Moses Direct Ownership Rights Deferred Share Units (cash settled) 56 - Grant of rights 6,780 $2.95
Mar 25/13 Mar 21/13 Sherman, Bernard Charles Control or Direction Common Shares 47 - Disposition by gift -2,003,000  
Mar 12/13 Jan 9/13 St. Hilaire, Francis Joseph Direct Ownership Common Shares 30 - Acquisition under a purchase/ownership plan 4,096 $1.48
Mar 12/13 Jan 9/13 Wolff-Long, Vicki Lynn Direct Ownership Common Shares 30 - Acquisition under a purchase/ownership plan 3,942 $1.61
Mar 12/13 Jan 9/13 Deezar, Leslie Paul Direct Ownership Common Shares 30 - Acquisition under a purchase/ownership plan 3,419 $1.49
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Sign up for an account or login above to see the past 6 months of SEDI filings sorted by insider.
No Markers (TSX Insider Summaries) for CNJ on May 21, 2013 [?]
To view marker data for the past week, sign up for an account or log in above.
To view more history, sign up for an account at inkresearch.com
Sector:  Healthcare Industry:  Pharmaceuticals
Key People
R. Craig Baxter
Chairman of the Board 		Kevin G. Taylor
Vice President - Business Development 		John A. Sedor
President, Chief Executive Officer, Director
Jeffrey Lamothe
Chief Financial Officer 		Gary Floyd
Chief Operating Officer 		Laura Saward
Chief Scientific Officer
Michael D. Adelman
Vice President - Commercial Operations 		Francis St. Hilaire
Vice President, General Counsel, Secretary 		Les Deezar
Vice President - Human Resources
Chris Sinclair
Vice President - Strategic Planning 		   
Company Contact
Address: 155 Innovation Drive
WINNIPEG MB R3T 5Y3
Tel: --
Website: www.cangene.com
IR: www.cangene.com/investor-relations
Business Overview
Cangene Corporation (Cangene) is a biopharmaceutical company in the business of developing, manufacturing, and commercializing products and technologies for global markets. It operates in two segments: biopharmaceutical operations and contract services. The biopharmaceutical operations segment consist of sales of approved products and non- specialty plasma. The contract-services segment consists of third-party contract-manufacturing revenues at the Company's Winnipeg facilities, as well as at Cangene bioPharma in Baltimore. It also provides commercial contract-manufacturing services, primarily through a United States-based subsidiary. The Company's products include Rho(D) Immune Globulin (Human) for Injection (WinRho) SDF, Hepatitis B Immune Globulin (Human) Injection (HepaGam B) and Varicella Zoster Immune Globulin (Human) (VariZIG). In February 2013, Ipsen SA and Inspiration Biopharmaceuticals Inc. announced the sale of hemophilia B product, IB1001 (recombinant FIX) to the Company.
Competitors with Recent Insider Filings
Cardiome Pharma (T:COM)
Transition Therapeutics (T:TTH)
Stem Cell Therapeutics (V:SSS)
 
Cangene Corporation Insider Report Only $20.00